FDA Approves First Nasal Spray for Treatment of Anaphylaxis

Upcoming Events

KHA Workers' Compensation Fund Safety Seminar -Oct. 24-25

KHA Workers' Compensation Fund, Inc., is a taxable workers' compensation pool operated by the Kansas Health Service Corporation. This fund was formed in 1991. It is organized in accordance with the workers' compensation statutes of the State of Kansas.KHA Workers' Compensation Fund's primary objective is to provide moderately priced workers' compensation insurance to Kansas Hospital Association members. Customer service is enhanced by the Fund Administrator and Safety Program Manager.

KCHC Annual Conference - Oct. 25

In today's highly competitive and fast-changing health care world, KCHC provides members with a unique opportunity to collaborate with their peers throughout the Greater Kansas City area. Mark your calendars and plan to attend KCHC's Fall Conference on Oct. 25. Watch for additional details.

Management and Leadership Training Three-Part Webinar Series - Part 1 - Oct. 29

This webinar series is designed for all health care managers and supervisors, including those in the nursing and allied health professions who want to fine-tune their management skills.

KFMC Health Equity Summit - Oct. 30

This year’s summit will address the challenges of resource deserts and explore solutions to improve health equity in underserved communities. Don’t miss this opportunity to collaborate, learn, and drive meaningful change.

KCMHC Fall Council Meeting - Oct. 31

In February 1999, the Missouri Hospital Association and KHA formed an integrated limited liability company called The Health Alliance of MidAmerica. The Alliance enables healthcare-related organizations to strengthen efforts in the areas of policy development and federal representation and advocacy.

Current Report Articles

‹‹ Back To List

FDA Approves First Nasal Spray for Treatment of Anaphylaxis

(Aug. 16, 2024) – On Aug. 9, the Food and Drug Administration announced the approval of Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who weigh at least 30 kilograms. This is the first approval for epinephrine for the treatment anaphylaxis that is not administered by injection. It is anticipated that the epinephrine nasal spray may reduce barriers to the rapid treatment of anaphylaxis. The FDA granted Neffy Fast Track designation for this application. The FDA granted the approval of Neffy to ARS Pharmaceuticals.
--Karen Braman

‹‹ Back To List

Communications

Upcoming Events

Recent News